Dermatology Unit, University of Campania Luigi Vanvitelli, Naples, Italy.
Dermatology Unit, G. Rummo Hospital, Benevento, Italy.
Ital J Dermatol Venerol. 2024 Jun;159(3):223-250. doi: 10.23736/S2784-8671.24.07664-3. Epub 2024 May 10.
SIDeMaST (Società Italiana di Dermatologia Medica, Chirurgica, Estetica e delle Malattie Sessualmente Trasmesse) contributed to the development of the present guideline on the systemic treatment of chronic plaque psoriasis. With the permission of EuroGuiDerm, SIDeMaST adapted the guideline to the Italian healthcare context to supply a reliable and affordable tool to Italian physicians who take care of patients affected by atopic dermatitis. The evidence- and consensus-based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. Four consensus conferences were held between December 2020 and July 2021. Twenty-nine experts (including clinicians and patient representatives) from 12 European countries participated. This first part of the guideline includes general information on its scope and purpose, the health questions covered, target users and a methods section. It also provides guidance on which patients should be treated with systemic therapies, as well as recommendations and detailed information on each systemic drug. The systemic treatment options discussed in the guideline comprise conventional immunosuppressive drugs (azathioprine, ciclosporin, glucocorticosteroids, methotrexate and mycophenolate mofetil), biologics (dupilumab, lebrikizumab, nemolizumab, omalizumab and tralokinumab) and janus kinase inhibitors (abrocitinib, baricitinib and upadacitinib). Part two of the guideline will address avoidance of provocation factors, dietary interventions, immunotherapy, complementary medicine, educational interventions, occupational and psychodermatological aspects, patient perspective and considerations for pediatric, adolescent, pregnant and breastfeeding patients.
SIDeMaST（意大利皮肤病医学、外科学、美容学和性传播疾病学会）为制定慢性斑块型银屑病的全身治疗指南做出了贡献。在 EuroGuiDerm 的许可下，SIDeMaST 将指南改编为意大利医疗保健背景，为照顾特应性皮炎患者的意大利医生提供可靠且负担得起的工具。特应性皮炎的循证和共识指南是根据 EuroGuiDerm 指南和共识声明制定手册开发的。在 2020 年 12 月至 2021 年 7 月期间举行了四次共识会议。来自 12 个欧洲国家的 29 名专家（包括临床医生和患者代表）参加了会议。该指南的这第一部分包括其范围和目的、涵盖的健康问题、目标用户和方法部分的一般信息。它还就哪些患者应接受全身治疗提供了指导，以及关于每种全身药物的建议和详细信息。指南中讨论的全身治疗选择包括传统免疫抑制剂（硫唑嘌呤、环孢素、糖皮质激素、甲氨蝶呤和霉酚酸酯）、生物制剂（度普利尤单抗、利匹鲁单抗、 nemolizumab、奥马珠单抗和特利鲁单抗）和 JAK 抑制剂（阿布昔替尼、巴瑞替尼和乌帕替尼）。指南的第二部分将涉及避免诱发因素、饮食干预、免疫疗法、补充医学、教育干预、职业和精神皮肤病学方面、患者视角以及儿科、青少年、孕妇和哺乳期患者的考虑因素。
